1 40 1 Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1097/RHU.0b013e3182155e8d" target="_blank" rel="noreferrer noopener">http://doi.org/10.1097/RHU.0b013e3182155e8d</a> Rights Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). Pages 145-147 Issue 3 Volume 17 Search for Full-text Locate full-text within NEOMED Library's e-journal collections <p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Type 1 Cryoglobulinemia Response to Thalidomide and Lenalidomide Publisher An entity responsible for making the resource available Jcr-Journal of Clinical Rheumatology Date A point or period of time associated with an event in the lifecycle of the resource 2011 2011-04 Subject The topic of the resource therapy; Rheumatology; patient; criteria; imids; multiple-myeloma; poems-syndrome; vasculitis; waldenstroms macroglobulinemia Creator An entity primarily responsible for making the resource Calabrese C; Faiman B; Martin D; Reu F; Calabrese L H Description An account of the resource Among the varying etiologies of cryoglobulinemia (Cg), type I Cg represents the rarest form and is most often associated with lymphoproliferative disorders such as non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, or multiple myeloma. Clinical manifestations are generally those of small-vessel vasculitis and/or hyperviscosity. The treatment of patients with type 1 disease generally consists of chemotherapy directed at the lymphoproliferative disorder or varying levels of empiric immunosuppression including apheresis, glucocorticoids, and cytotoxic agents. In recent years, anecdotes of biologic and/or immunomodulatory therapy with rituximab and thalidomide have been reported.(1-4) Occasionally. patients present with severe type 1 cryoglobulinemic disease in the absence of a defined malignancy but with monoclonal gammopathy of otherwise undetermined significance (MGUS); the treatment of such patients is controversial.(5,6) We recently treated such a patient with traditional immunosuppressives and rituximab but found him ultimately to respond only to thalidomide and its congener, lenalidomide. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1097/RHU.0b013e3182155e8d" target="_blank" rel="noreferrer noopener">10.1097/RHU.0b013e3182155e8d</a> Format The file format, physical medium, or dimensions of the resource Journal Article or Conference Abstract Publication 2011 Calabrese C Calabrese L H criteria Department of Internal Medicine Faiman B imids Jcr-Journal of Clinical Rheumatology Journal Article or Conference Abstract Publication Martin D multiple-myeloma NEOMED College of Medicine Patient poems-syndrome Reu F Rheumatology therapy vasculitis waldenstroms macroglobulinemia